Liquidia Corporation $(LQDA)$, a biopharmaceutical company focused on developing therapies for rare cardiopulmonary diseases, has received U.S. Food and Drug Administration (FDA) approval for its product, YUTREPIA™ (treprostinil) inhalation powder. This innovative prostacyclin analog is designed for adults with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) to enhance exercise ability. YUTREPIA, enabled by Liquidia's proprietary PRINT™ technology, stands out as the first and only prostacyclin dry-powder formulation, offering benefits such as deep-lung delivery and easy usability. Despite this milestone, Liquidia faces legal challenges from United Therapeutics Corporation, which has filed a complaint alleging patent infringement to prevent the commercialization of YUTREPIA. Liquidia is prepared to address these challenges as it progresses with its commercial launch plans.